Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus | Zendy

David Z.I. Cherney | Zendy; Bruce A. Perkins | Zendy; Nima Soleymanlou | Zendy; M Maione | Zendy; Vesta Lai | Zendy; Alana Lee | Zendy; Nora Fagan | Zendy; Hans J. Woerle | Zendy; Odd Erik Johansen | Zendy; Uli C. Broedl | Zendy; Maximilian von Eynatten | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

Author(s) -

David Z.I. Cherney,

Bruce A. Perkins,

Nima Soleymanlou,

M Maione,

Vesta Lai,

Alana Lee,

Nora Fagan,

Hans J. Woerle,

Odd Erik Johansen,

Uli C. Broedl,

Maximilian von Eynatten

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.005081

Subject(s) - empagliflozin , medicine , renal function , glomerular hyperfiltration , effective renal plasma flow , endocrinology , renal blood flow , diabetes mellitus , tubuloglomerular feedback , plasma renin activity , aldosterone , filtration fraction , type 2 diabetes , urology , renin–angiotensin system , blood pressure , diabetic nephropathy

The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks' sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects with type 1 diabetes mellitus (T1D).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research